January 29, 2015 - International Stem Cell Corporation , a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that the company has completed the required preclinical studies and plans to begin the phase 1/2a clinical study of the company's cell therapy for the treatment of Parkinson's disease in Australia within the next few months. ISCO has formed an Australian subsidiary, Cyto Therapeutics Pty Ltd, to manage the regulatory submission to the Australian Therapeutics Goods Administration and the up-and-coming clinical study.
http://ift.tt/1zi0kLJ
http://ift.tt/1zi0kLJ
No comments:
Post a Comment